Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C

Recent studies have shown that serum vitamin D deficiency is a negative predictor of response to peginterferon plus ribavirin therapy for Caucasian patients with chronic hepatitis C (CHC). Whether vitamin D receptor (VDR) gene polymorphisms associate with antiviral response in Asian CHC patients rem...

Full description

Bibliographic Details
Main Authors:	Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Chien-Hung Chen, Jing-Houng Wang, Chuan-Mo Lee
Format:	Article
Language:	English
Published:	Elsevier 2016-04-01
Series:	Journal of the Formosan Medical Association
Subjects:	Asia hepatitis C interferon sustained virological response vitamin D receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664615003794

Similar Items

Association of genetic variations in <it>GNB1</it> with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan
by: Lim Yun-Ping, et al.
Published: (2012-11-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report
by: Lucas C. Quarantini, et al.

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
by: Ching-Sheng Hsu, et al.
Published: (2014-10-01)

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
by: Marcelo Cunio Machado Fonseca, et al.

Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy
by: Shin-Yu Lu, et al.
Published: (2009-12-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
by: Osamu Yokosuka, et al.
Published: (2012-08-01)

Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
by: Hamid Kalantari, et al.
Published: (2014-01-01)

Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C
by: Fernando Lopes Gonçales Jr., et al.

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
by: Ide K, et al.
Published: (2016-03-01)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019-02-01)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
by: Zheng C, et al.
Published: (2019-04-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy
by: Hu CC, et al.
Published: (2018-04-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin
by: Kuo-Chih Tseng, et al.
Published: (2017-05-01)

Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C Recombinant Interferon alfa-2b plus Ribavirin in treatment of chronic hepatitis C
by: Yoan Antonio Sánchez Rodríguez, et al.
Published: (2010-06-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
by: Ming-Chao Tsai, et al.
Published: (2009-09-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
by: Suh Yoon Yang, et al.
Published: (2015-06-01)

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
by: D Hartwell, et al.
Published: (2011-04-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients
by: Chuan-Mo Lee, et al.
Published: (2016-06-01)

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
by: Liu Jun-Ying, et al.
Published: (2012-09-01)

Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C
by: Tseng CW, et al.
Published: (2016-03-01)

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
by: Nae-Yun Heo, et al.
Published: (2014-06-01)

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
by: Zubia Jamil, et al.
Published: (2018-05-01)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
by: Sung Yong Han, et al.
Published: (2021-05-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
by: Jae Yoon Jeong, et al.
Published: (2020-09-01)

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
by: Chen SL, et al.
Published: (2023-05-01)

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C
by: Bilgehan AYGEN, et al.
Published: (2004-09-01)